Sökning: onr:"swepub:oai:DiVA.org:uu-520215" > Were cancer patient...
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 07084naa a2200733 4500 | |
001 | oai:DiVA.org:uu-520215 | |
003 | SwePub | |
008 | 240112s2023 | |||||||||||000 ||eng| | |
009 | oai:prod.swepub.kib.ki.se:154350797 | |
024 | 7 | a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-5202152 URI |
024 | 7 | a https://doi.org/10.1016/j.lanepe.2023.1006802 DOI |
024 | 7 | a http://kipublications.ki.se/Default.aspx?queryparsed=id:1543507972 URI |
040 | a (SwePub)uud (SwePub)ki | |
041 | a engb eng | |
042 | 9 SwePub | |
072 | 7 | a ref2 swepub-contenttype |
072 | 7 | a art2 swepub-publicationtype |
100 | 1 | a Johansson, Anna L., Vu Karolinska Institutet,Canc Registry Norway, POB 5313 Majorstuen, N-0304 Oslo, Norway.;Karolinska Inst, Dept Med Epidemiol & Biostat, POB 281, SE-17177 Stockholm, Sweden.4 aut |
245 | 1 0 | a Were cancer patients worse off than the general population during the COVID-19 pandemic? :b A population-based study from Norway, Denmark and Iceland during the pre-vaccination era |
264 | 1 | b Elsevier,c 2023 |
338 | a electronic2 rdacarrier | |
520 | a Background In a population-based setting, we investigated the risks of testing positive for SARS-CoV-2 and developing severe COVID-19 outcomes among cancer patients compared with the general population.Methods In nationwide cohorts, we identified all individuals in Norway, Denmark and Iceland who tested positive for SARS-CoV-2 or had a severe COVID-19 outcome (hospitalisation, intensive care, and death) from March until December 2020, using data from national health registries. We estimated standardised incidence ratios (SIRs) with 95% confidence intervals (CIs) comparing cancer patients with the general population.Findings During the first wave of the pandemic, cancer patients in Norway and Denmark had higher risks of testing SARS-CoV-2 positive compared to the general population. Throughout 2020, recently treated cancer patients were more likely to test SARS-CoV-2 positive. In Iceland, cancer patients experienced no increased risk of testing positive. The risk of COVID-19-related hospitalisation was higher among cancer patients diagnosed within one year of hospitalisation (Norway: SIR = 2.43, 95% CI 1.89-3.09; Denmark: 2.23, 1.96-2.54) and within five years (Norway: 1.58, 1.35-1.83; Denmark: 1.54, 1.42-1.66). Risks were higher in recently treated cancer patients and in those diagnosed with haematologic malignancies, colorectal or lung cancer. Risks of COVID-19-related intensive care and death were higher among cancer patients. Interpretation Cancer patients were at increased risk of testing positive for SARS-CoV-2 during the first pandemic wave when testing availability was limited, while relative risks of severe COVID-19 outcomes remained increased in cancer patients throughout 2020. Recent cancer treatment and haematologic malignancy were the strongest risk factors. | |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Cancer och onkologi0 (SwePub)302032 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cancer and Oncology0 (SwePub)302032 hsv//eng |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Infektionsmedicin0 (SwePub)302092 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Infectious Medicine0 (SwePub)302092 hsv//eng |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Hälsovetenskapx Folkhälsovetenskap, global hälsa, socialmedicin och epidemiologi0 (SwePub)303022 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Health Sciencesx Public Health, Global Health, Social Medicine and Epidemiology0 (SwePub)303022 hsv//eng |
653 | a COVID-19 | |
653 | a Coronavirus disease 2019 | |
653 | a SARS-CoV-2 | |
653 | a Severe acute respiratory syndrome coronavirus 2 | |
653 | a Cancer | |
653 | a Hospitalisation | |
653 | a Critical care outcomes | |
653 | a Intensive care | |
653 | a Mortality | |
653 | a Nordic | |
653 | a Denmark | |
653 | a Norway | |
653 | a Iceland | |
700 | 1 | a Skog, Annau Canc Registry Norway, POB 5313 Majorstuen, N-0304 Oslo, Norway.4 aut |
700 | 1 | a Johannesen, Tom Borgeu Canc Registry Norway, POB 5313 Majorstuen, N-0304 Oslo, Norway.4 aut |
700 | 1 | a Myklebust, Tor ageu Canc Registry Norway, POB 5313 Majorstuen, N-0304 Oslo, Norway.;More & Romsdal Hosp Trust, Dept Res & Innovat, Alesund, Norway.4 aut |
700 | 1 | a Skovlund, Charlotte Wesselu Danish Canc Soc Res Ctr, Danish Canc Soc, Canc Surveillance & Pharmacoepidemiol, Strandboulevarden 49, DK-2100 Copenhagen, Denmark.4 aut |
700 | 1 | a Morch, Lina Steinrudu Danish Canc Soc Res Ctr, Danish Canc Soc, Canc Surveillance & Pharmacoepidemiol, Strandboulevarden 49, DK-2100 Copenhagen, Denmark.4 aut |
700 | 1 | a Friis, Sorenu Danish Canc Soc Res Ctr, Danish Canc Soc, Canc Surveillance & Pharmacoepidemiol, Strandboulevarden 49, DK-2100 Copenhagen, Denmark.4 aut |
700 | 1 | a Gamborg, Madsu Danish Canc Soc Res Ctr, Danish Canc Soc, Canc Surveillance & Pharmacoepidemiol, Strandboulevarden 49, DK-2100 Copenhagen, Denmark.4 aut |
700 | 1 | a Kristiansen, Marnar Frioheimu Fac Hlth Sci, Ctr Hlth Sci, Torshavn, Faroe Islands.;Natl Hosp Faroe Isl, Torshavn, Faroe Islands.4 aut |
700 | 1 | a Pettersson, Davidu Natl Board Hlth & Welf, SE-10630 Stockholm, Sweden.4 aut |
700 | 1 | a Olafsdottir, Elinborg J.u Iceland Canc Soc, ICS Res & Registrat Ctr, POB 5420, IS-105 Reykjavik, Iceland.4 aut |
700 | 1 | a Birgisson, Helgiu Iceland Canc Soc, ICS Res & Registrat Ctr, POB 5420, IS-105 Reykjavik, Iceland.4 aut |
700 | 1 | a Palsson, Runolfuru Landspitali The Natl Univ Hosp Iceland, Saemundargata 2, IS-102 Reykjavik, Iceland.;Univ Iceland, Reykjavik, Iceland.4 aut |
700 | 1 | a Eythorsson, Eliasu Landspitali The Natl Univ Hosp Iceland, Saemundargata 2, IS-102 Reykjavik, Iceland.4 aut |
700 | 1 | a Irenaeus, Sandrau Uppsala universitet,Cancerimmunterapi,Akadem Sjukhuset, Reg Canc Ctr Cent Sweden, SE-75185 Uppsala, Sweden.4 aut0 (Swepub:uu)sanir765 |
700 | 1 | a Lambe, Matsu Karolinska Inst, Dept Med Epidemiol & Biostat, POB 281, SE-17177 Stockholm, Sweden.;Akadem Sjukhuset, Reg Canc Ctr Cent Sweden, SE-75185 Uppsala, Sweden.4 aut |
700 | 1 | a Ursin, Giskeu Canc Registry Norway, POB 5313 Majorstuen, N-0304 Oslo, Norway.;Univ Oslo, Inst Basic Med Sci, Oslo, Norway.;Univ Southern Calif, Dept Prevent Med, Los Angeles, CA USA.4 aut |
710 | 2 | a Karolinska Institutetb Canc Registry Norway, POB 5313 Majorstuen, N-0304 Oslo, Norway.;Karolinska Inst, Dept Med Epidemiol & Biostat, POB 281, SE-17177 Stockholm, Sweden.4 org |
773 | 0 | t The Lancet Regional Healthd : Elsevierg 31q 31x 2666-7762 |
856 | 4 | u https://doi.org/10.1016/j.lanepe.2023.100680y Fulltext |
856 | 4 | u https://uu.diva-portal.org/smash/get/diva2:1826870/FULLTEXT01.pdfx primaryx Raw objecty fulltext:print |
856 | 4 8 | u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-520215 |
856 | 4 8 | u https://doi.org/10.1016/j.lanepe.2023.100680 |
856 | 4 8 | u http://kipublications.ki.se/Default.aspx?queryparsed=id:154350797 |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.